REGN14256
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for REGN14256, covering 2024-04-26 to 2024-04-26. Get the full timeline:
Most recent: Clinical Trial Update: COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease [Phase 1, Phase 2]